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ARTICLE
High-efﬁciency RNA-based reprogramming of
human primary ﬁbroblasts
Igor Kogut1,2, Sandra M. McCarthy1,2, Maryna Pavlova1,2, David P. Astling3, Xiaomi Chen1,2, Ana Jakimenko1,2,
Kenneth L. Jones4, Andrew Getahun5, John C. Cambier5, Anna M.G. Pasmooij6, Marcel F. Jonkman6,
Dennis R. Roop1,2 & Ganna Bilousova1,2,7
Induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine; how-
ever, their potential clinical application is hampered by the low efﬁciency of somatic cell
reprogramming. Here, we show that the synergistic activity of synthetic modiﬁed mRNAs
encoding reprogramming factors and miRNA-367/302s delivered as mature miRNA mimics
greatly enhances the reprogramming of human primary ﬁbroblasts into iPSCs. This syner-
gistic activity is dependent upon an optimal RNA transfection regimen and culturing condi-
tions tailored speciﬁcally to human primary ﬁbroblasts. As a result, we can now generate up
to 4,019 iPSC colonies from only 500 starting human primary neonatal ﬁbroblasts and
reprogram up to 90.7% of individually plated cells, producing multiple sister colonies. This
methodology consistently generates clinically relevant, integration-free iPSCs from a variety
of human patient’s ﬁbroblasts under feeder-free conditions and can be applicable for the
clinical translation of iPSCs and studying the biology of reprogramming.
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Reprogramming somatic cells into induced pluripotent stemcells (iPSCs) through ectopic expression of the transcrip-tion factors OCT4, KLF4, SOX2, and cMYC (known as the
Yamanaka factors) provides an unlimited supply of cells with
embryonic stem cell (ESC)-like properties1–4. Despite great
advances in developing reprogramming approaches, the efﬁciency
of iPSC generation remains relatively low5,6, hampering the
potential application of iPSC technology in clinical and research
settings.
To overcome low reprogramming efﬁciency, a variety of
reprogramming modulators have been identiﬁed to date. How-
ever, when combined with the Yamanaka factors, many of these
modulators produce only a modest enhancement of overall
reprogramming efﬁciency6–9, while others function exclusively on
murine cells10–12. The expression level and stoichiometry of
reprogramming factors may also inﬂuence the efﬁciency of
reprogramming13; however, only a few reprogramming protocols
allow for the precise control over these parameters. Reprogram-
ming with synthetic capped mRNAs containing modiﬁed
nucleobases (mod-mRNA) is the most promising among these
approaches due to its relatively high efﬁciency (up to 4.4%)14,15,
low activation of an innate antiviral response14, and production
of high-quality, clinically relevant iPSCs6. Although the mod-
mRNA-based approach successfully reprograms established,
long-lived ﬁbroblast cell lines such as BJs14,15, this method is
inconsistent when applied to freshly isolated patient’s cells6. This
observation suggests that the conditions optimized for established
ﬁbroblast lines may not fully support the reprogramming of
primary cells due to differences in culturing conditions, RNA
transfection efﬁciency, and gene expression proﬁles between these
cell types16. Thus, an optimal regimen for the mod-mRNA-based
reprogramming of human primary ﬁbroblasts has not been
established.
Here, we sought to overcome the inconsistencies of the mod-
mRNA-based reprogramming approach and develop an efﬁcient,
integration-free reprogramming protocol adapted speciﬁcally to
human primary ﬁbroblasts. To accomplish this goal, we supple-
mented the mod-mRNA cocktail of reprogramming factors15
with ESC-speciﬁc miRNA-367/302s17 as mature miRNA mimics.
The cocktail of mature miRNA-367/302s mimics is referred to as
m-miRNAs in this study. The miRNAs-367/302s family of
miRNAs has been previously shown to induce pluripotency in
somatic cells17 and enhance the efﬁciency of the mod-mRNA-
based reprogramming6,7. We also optimized the RNA transfec-
tion regimen, cell seeding, and culturing conditions during
reprogramming. We show that the combination of the repro-
gramming mod-mRNAs and m-miRNAs enhances the genera-
tion of iPSCs from human primary ﬁbroblasts in a synergistic
manner. Because of this synergism, we can reprogram human
patient’s ﬁbroblasts with an efﬁciency that surpasses all previously
published integration-free protocols. Our protocol employs
feeder-free culture conditions, produces clinically relevant iPSCs,
and is capable of reprogramming even an individually plated
human cell. Our data suggest that the reprogramming efﬁciency
of other cell types may be greatly improved by optimizing both
culture and RNA transfection conditions.
Results
Optimized delivery of RNAs enhances reprogramming. We
speculated that the efﬁciency of mod-mRNA-based reprogram-
ming could be improved by incorporating ESC-speciﬁc m-miR-
NAs. In addition, since high cell cycling was previously shown to
promote more efﬁcient reprogramming18, we decided to initiate
reprogramming with a low seeding density, which would allow
input cells to go through more cell cycles. Finally, our ultimate
goal was to develop a reprogramming protocol that was clinically
relevant; therefore, we focused on optimizing feeder-free plating
conditions.
We initially pre-screened the mod-mRNA reprogramming
protocols that utilized feeder-free plating conditions and
eventually selected one which used a modiﬁed version of OCT4
fused with the MyoD transactivation domain (called M3O)19 in
combination with ﬁve other reprogramming factors (SOX2,
KLF4, cMYC, LIN28A, and NANOG)15. This 6-factor mod-
mRNA reprogramming cocktail is referred to as 5fM3O mod-
mRNAs (Supplementary Fig. 1a). Transfecting this 5fM3O mod-
mRNA cocktail as previously described15 resulted in a repro-
gramming efﬁciency of <0.5% (Supplementary Fig. 1b, c), which
is consistent with published reports on mod-mRNA reprogram-
ming6,14,15. When ﬁbroblasts were plated at a low seeding
density, we observed substantial cytotoxicity and cell death within
4–5 days of initiating mod-mRNA reprogramming (Supplemen-
tary Fig. 1b, c). Similar cytotoxicity and cell death was observed
when the 5fM3O mod-mRNA cocktail was supplemented with m-
miRNAs (see Methods section).
To identify conditions that would support the growth of low-
density ﬁbroblast cultures during co-transfections with 5fM3O
mod-mRNAs and m-miRNAs, we screened various reprogram-
ming media and RNA transfection reagents. We determined that
RNA transfected with Lipofectamine RNAiMAX (RNAiMAX) at
24 h intervals allowed for the survival of low-density ﬁbroblasts
(500 cells per well of a 6-well format dish) cultured in the knock-
out serum replacement (KOSR) reprogramming medium. How-
ever, despite their survival, the cells did not undergo complete
reprogramming. We hypothesized that reprogramming failed due
to inefﬁcient mod-mRNA transfection (Fig. 1a and Supplemen-
tary Fig. 2; see Supplementary Figs. 2 and 3a for the results
obtained on an independent human primary neonatal ﬁbroblast
line, FN1). To optimize the transfection efﬁciency of cells grown
in KOSR medium, we used mod-mRNA encoding mWasabi to
evaluate several different transfection buffers in combination with
assessing the effect of adjusting the pH of the buffers. The highest
transfection efﬁciency using the manufacturer’s recommended
transfection buffer for RNAiMAX, Opti-MEM, was achieved
when its pH was adjusted from the original 7.2–7.3 to 8.2 (up to
~65% of mWasabi positive cells) (Fig. 1a and Supplementary
Figs. 2 and 3a). We also found that phosphate-buffered saline
(PBS) could be used as an alternative transfection buffer for
RNAiMAX (Fig. 1a and Supplementary Fig. 3a). Interestingly,
altering the pH or composition of transfection buffers did not
affect the transfection efﬁciency of ﬂuorescently labeled AllStars
Negative small interfering RNA (siRNA), which was used as a
control for the transfection of miRNA mimics, probably due to
intrinsic properties of these RNAs (Supplementary Fig. 4).
Therefore, to streamline the reprogramming procedure, m-
miRNAs were delivered using the same transfection buffers as
mod-mRNAs in the rest of our studies.
Employing Opti-MEM adjusted to a pH of 8.2 (Opti-MEM-
8.2) as the transfection buffer for RNAiMAX, we reassessed the
reprogramming of neonatal ﬁbroblasts cultured in KOSR
medium using mod-mRNAs and m-miRNAs transfections. The
most efﬁcient, consistent, and cost-effective mod-mRNA/m-
miRNA reprogramming regimen is depicted in Fig. 1b. It
involves seven transfections of 600 ng of 5fM3O mod-mRNA
cocktail and 20 pmol of m-miRNAs per well of a 6-well format
dish performed every 48 h using Opti-MEM-8.2 as the transfec-
tion buffer. This protocol enabled us to achieve an ultra-high
reprogramming efﬁciency yielding up to 4,019 (3,896 ± 131.14;
mean ± s.d.; n= 3) (Fig. 1c, d and Table 1) and 3,391 (3,132 ±
240.04; mean ± s.d.; n= 3) (Supplementary Fig. 3b, c and Table 1)
TRA-1-60-positive colonies from 500 initially plated cells using
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two independent primary neonatal ﬁbroblast lines, FN2 and FN1,
respectively. These reprogramming efﬁciencies were higher than
the efﬁciencies obtained with the previously published mod-
mRNA reprogramming protocol15 using the same ﬁbroblast lines
(Supplementary Fig. 1b, c; 50,000 cells plated per well) (P < 0.0001
for both FN1 and FN2 using the unpaired two-tailed Student’s
ttest).
We found that three transfections performed every 48 h were
the minimum required to obtain iPSC colonies, and transfections
performed every 72 h showed a reduced capacity to generate
iPSCs as compared to 48 h transfection intervals (Fig. 2). No
TRA-1-60-positive colonies arose when regular, unadjusted Opti-
MEM at pH 7.3 (Opti-MEM-7.3) was used as the transfection
buffer (Fig. 1c, d and Supplementary Fig. 3b, c). Reprogramming
also failed when Opti-MEM at pH 8.6 was used as the
transfection buffer despite the relatively high efﬁciency of
mWasabi mRNA transfection achieved under this pH (Fig. 1a,
c, d and Supplementary Fig. 3a–c). The regimen performed with
Opti-MEM at pH 8.6 appeared to be cytotoxic, probably due to
the degradation of RNA at this higher pH. Degraded RNA most
likely increases the innate immunity response, which in turn
induces cytotoxicity and reduces the reprogramming efﬁciency.
+–neg
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Varying the concentrations of m-miRNAs in combination with
600 ng of 5fM3O mod-mRNAs did not lead to a substantial
change in reprogramming efﬁciency (Fig. 3). Transfections every
48 h with m-miRNAs in combination with d2eGFP as a negative
control failed to induce iPSC formation (Fig. 1c, d and
Supplementary Fig. 3b, c). Interestingly, while the transfection
of 5fM3O mod-mRNAs alone at 48 h intervals resulted in a high
yield of TRA-1-60-positive colonies (Fig. 1c, d and Supplemen-
tary Fig. 3b, c), we were not successful in establishing long-lived
iPSC lines from these colonies. This suggests that our transfection
regimen requires both m-miRNAs and 5fM3O mod-mRNAs to
produce stably reprogrammed iPSCs. Note that substituting M3O
with wild-type OCT4 in the 6-factor cocktail (5fOCT4) resulted
in a marked reduction of the reprogramming efﬁciency (Fig. 1c, d
and Supplementary Fig. 3b, c). Therefore, only the 5fM3O mod-
mRNA cocktail was used in the rest of our studies.
When 5fM3O mod-mRNAs were delivered alone or in
combination with m-miRNAs every 24 h, the high cytotoxicity
of this regimen prevented the reproducible generation of iPSCs.
This cytotoxicity likely resulted from an excess of exogenous
mod-mRNAs, which is known to cause the activation of a cellular
immune response14. Consistent with the high cytotoxicity of
mod-mRNAs, a higher transfection efﬁciency of mod-mRNAs
achieved with PBS at pH 7.9 as compared to Opti-MEM-8.2
(Fig. 1a and Supplementary Fig. 3a) did not translate into more
efﬁcient reprogramming due to poor survival of input cells
(Fig. 1c, e and Supplementary Fig. 3b, d). Instead, the amount of
5fM3O mod-mRNAs delivered with PBS at pH 7.9 had to be
reduced to improve the survival and reprogramming efﬁciency of
ﬁbroblasts (Fig. 1c, e and Supplementary Fig. 3b, d).
Collectively, our results indicate that the ﬁne-tuning of
exogenous reprogramming mod-mRNAs levels in combination
with m-miRNAs synergistically improves the efﬁciency of iPSC
generation from human primary ﬁbroblasts.
Low density of input cells improves reprogramming efﬁciency.
To address how the initial seeding density of human primary cells
affects the reprogramming efﬁciency of our optimized RNA-
based approach (Fig. 1b), we performed a series of reprogram-
ming experiments using human primary neonatal ﬁbroblasts
plated at different densities (Fig. 4a; see Supplementary Fig. 5 for
the results obtained on an independent human primary neonatal
ﬁbroblast line, FN1). We found that the highest initial seeding
density that allowed for the efﬁcient generation of TRA-1-60-
positive colonies was 10,000 cells per well in a 6-well format dish.
The efﬁciency of reprogramming gradually increased with redu-
cing the starting density of input cells (Fig. 4a and Supplementary
Fig. 5). Colonies formed poorly at an initial seeding density of
50,000 cells per well and above due to cell overcrowding in the
process of reprogramming.
Reprogramming efﬁciency is traditionally calculated as the
number of iPSC colonies generated divided by the number of
input cells. If this method is used to calculate the efﬁciency of our
optimal reprogramming regimen, an efﬁciency of ~800% is
obtained. This high efﬁciency suggests that multiple sister iPSC
colonies must be derived from a single parental cell. To address
the formation of multiple sister iPSC colonies, we performed a
single-cell reprogramming experiment. We were able to repro-
gram up to 90.7% of individually plated single cells (Fig. 4b), with
the majority of input cells producing multiple TRA-1-60-positive
colonies (Fig. 4b, c). If m-miRNAs were excluded from the
regimen, the efﬁciency of single-cell reprogramming dropped
drastically (Fig. 4b), further demonstrating the synergism between
reprogramming mod-mRNAs and m-miRNAs on the efﬁciency
of iPSC generation.
The RNA-based approach reprograms a variety of ﬁbroblasts.
Since our goal was to develop a clinically relevant protocol, we
evaluated the applicability of our approach for the reprogram-
ming of human primary ﬁbroblasts derived from a variety of
human subjects. In addition to three neonatal ﬁbroblast lines, we
successfully reprogrammed ﬁbroblasts derived from patients with
inherited skin blistering disorders and Down syndrome, as well as
from three healthy adult individuals of 40 (F40), 50 (F50), and 62
(F62) years of age with high, albeit different, efﬁciencies (Table 1
and Supplementary Fig. 6). The protocol is more cytotoxic to
adult and especially disease-speciﬁc lines, probably due to the
activation of senescence-associated pathways in these cells20.
Therefore, the reprogramming of adult cells was initiated at
higher cell numbers and required adjusting plating densities
based on the patient’s age (Table 1).
As a more stringent test of the robustness of our reprogram-
ming protocol, we assessed the ability of the method to reprogram
senescent ﬁbroblasts. The F50 ﬁbroblast line was serially passaged
until more than 91% of cells exhibited a senescent phenotype
(Fig. 5a). The reprogramming of this senescent line took only
16 days and resulted in an efﬁciency of ~0.33% (Table 1 and
Supplementary Fig. 6), which surpassed the reprogramming
efﬁciency previously reported for senescent ﬁbroblasts using an
integrating lentiviral approach21. To our knowledge, this is the
ﬁrst report of the successful reprogramming of senescent human
cells with an integration-free approach. The iPSCs derived from
these senescent ﬁbroblasts exhibited the expected markers of
rejuvenation, including the downregulation of p21
Fig. 1 Optimal delivery of mod-mRNAs and m-miRNAs enhances the reprogramming of human primary ﬁbroblasts. a Transfection efﬁciency (top) and
mean ﬂuorescence intensity (bottom) of human primary neonatal ﬁbroblasts (FN2) transfected with 500 ng of mod-mRNA encoding mWasabi, using
indicated transfection buffers, as determined by ﬂow cytometry 24 h post transfection. Error bars, mean ± s.d. for all panels (n= 3). The results are
reproducible using an independent primary neonatal ﬁbroblast line, FN1 (Supplementary Fig. 3a). b Schematic diagram of the optimized RNA-based
reprogramming regimen with RNAs delivered using Opti-MEM adjusted to a pH of 8.2 as the transfection buffer for RNAiMAX. c Effect of mod-mRNA
titration and the addition of m-miRNAs on the reprogramming of human primary neonatal ﬁbroblasts (FN2). All reprogramming conditions were initiated at
500 cells per well of a 6-well format dish. Cells were transfected every 48 h with differing amounts of mod-mRNAs encoding mWasabi (transfection
control) and either d2eGFP as a negative control or 6-factor reprogramming cocktails containing either M3O (5fM3O) or OCT4 (5fOCT4). Mod-mRNA
transfections were performed alone or in combination with m-miRNAs or AllStars Negative control siRNA (neg) transfections, using the indicated
transfection buffers. The number of resulting TRA-1-60-positive colonies on day 18 of the indicated regimens are plotted. Error bars, mean ± s.d. (n= 3).
The yield of TRA-1-60-positive colonies was compared between the regimens performed in the presence or absence of m-miRNAs. P values were
calculated using the unpaired two-tailed Student’s t test. **P < 0.01, ***P < 0.001, ****P < 0.0001. d Representative TRA-1-60-stained reprogramming wells
corresponding to conditions indicated in c for Opti-MEM as the transfection buffer. e Representative TRA-1-60-stained reprogramming wells
corresponding to conditions indicated in c for PBS as the transfection buffer. Solid black arrows indicate optimal conditions for mod-mRNA transfections in
a and iPSC colony generation in c, d. All scale bars, 10mm. The results of reprogramming experiments are reproducible using an independent primary
neonatal ﬁbroblast line, FN1 (Supplementary Fig. 3b–d)
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(Supplementary Fig. 7), reactivation of telomerase (Supplemen-
tary Fig. 8), and elongation of telomeres (Fig. 5b).
Characterization of the generated iPSC lines. Multiple iPSC
lines were derived from neonatal, adult, and senescent human
ﬁbroblasts using the optimized RNA-based approach (Supple-
mentary Table 1). All established lines exhibited appropriate
karyotypes (Supplementary Table 1 and Supplementary Fig. 9)
and showed molecular and functional characteristics of plur-
ipotent stem cells. The transcriptional proﬁles of selected iPSC
lines (Supplementary Table 2) appeared to be similar to those of
human ESC lines (Fig. 6a and Supplementary Fig. 10). The
generated iPSC lines clustered closely to the human ESC lines H1
and H9 when the global transcriptional proﬁles were subjected to
the principal components analysis (Fig. 6a). The expression of the
pluripotency markers OCT4, NANOG, SOX2, LIN28A, TRA-1-
81, and SSEA-4 was validated at the protein level (Figs. 5c and 6b
and Supplementary Figs. 11, 12), and the demethylation of the
OCT4 promoter was conﬁrmed by bisulﬁte sequencing (Fig. 6c).
The generated iPSCs successfully underwent directed differ-
entiation into βIII-Tubulin (TUJ1)-positive neurons (ectoderm)
and cytokeratin Endo-A-positive endodermal cells (Figs. 5d and
6d), and produced mesoderm-derived beating cardiomyocytes
from embryoid bodies (Supplementary Movies 1–5). The
developmental potential of the generated iPSCs was further
conﬁrmed in vivo by the formation of teratomas that consisted of
cell types of all three germ layers (Figs. 5e and 6e and
Supplemetary Fig. 13).
Gene expression changes in cells undergoing reprogramming.
To address the potential mechanisms behind the increased
reprogramming efﬁciency observed in our protocol vs. the con-
ventional 5fM3O mod-mRNA reprogramming protocol15, we
analyzed the transcript levels of a selected set of genes at different
time points during the ﬁrst 16 days of reprogramming using the
Nanostring nCounter Gene Expression Assay. Two independent
human primary neonatal ﬁbroblast lines, FN1 and FN2, were
subjected to a time-course gene expression analysis during
reprogramming performed with different regimens as indicated
in Supplementary Fig. 14. Our optimized RNA-based approach
(called 5fM3O+m-miRNAs) initiated at 500 cells per well
showed lower levels of transcripts encoding innate immunity
genes than the previously published feeder-free 5fM3O mod-
mRNA reprogramming protocol15 (called control 5fM3O
reprogramming) (FN2: Fig. 7a and Supplementary Fig. 15a; FN1:
Supplementary Figs. 16a and 17a). This ﬁnding correlated with a
lower level of exogenous reprogramming mod-mRNAs detected
in the 5fM3O+m-miRNA regimen (FN2: Fig. 7a and Supple-
mentary Fig. 15a; FN1: Supplementary Figs. 16a and 17a) and
presumably contributed to the improved reprogramming efﬁ-
ciency. The 5fM3O+m-miRNA reprogramming initiated at 500
cells per well yielded higher expression levels of several cell cycle
promoting genes as compared to the 5fM3O+m-miRNA
reprogramming initiated at higher seeding densities (10,000 or
50,000 cells per well) or the control 5fM3O reprogramming (FN2:
Fig. 7b and Supplementary Fig. 15b; FN1: Supplementary
Figs. 16b and 17b). The activation of cell cycle genes correlated
with the cell expansion rate for all assessed regimens for both cell
lines (FN2: Fig. 7b; FN1: Supplementary Fig. 16b). The expression
of both p21CIP1 and p57 remained low in the 5fM3O+m-
miRNA approach as compared to the control 5fM3O repro-
gramming (FN2: Fig. 7b; FN1: Supplementary Fig. 16b) and may
be attributed to optimal levels of expression of reprogramming
factors.
We also analyzed transcript levels of genes known to be
involved in chromatin remodeling and pluripotency maintenance
with a particular focus on known predictive markers of
pluripotency such as UTF1, LIN28A, DPPA2, and SOX222
(FN2: Fig. 7c and Supplementary Fig. 15c; FN1: Supplementary
Figs 16c and 17c). The activation of the majority of chromatin
remodeling and pluripotency genes occurred several days earlier
in the 5fM3O+m-miRNA approach as compared to the control
5fM3O reprogramming (FN2: Fig. 7c and Supplementary Fig. 15c;
FN1: Supplementary Figs 16c and 17c). Thus, the optimized
RNA-based approach not only reduces the expression of innate
immunity genes, but also leads to the robust activation of
pluripotency-associated genes.
Discussion
In this study, we developed a highly optimized, non-integrating,
combinatorial RNA-based reprogramming approach that allowed
us to reprogram multiple normal and disease-speciﬁc human
ﬁbroblast lines into iPSCs at an ultra-high efﬁciency. The
approach is cost effective, provides an opportunity to shorten the
time between the biopsy and the generation of clinically relevant,
high-quality iPSC lines, and allows for the production of iPSCs
from as few as a single cell in a feeder-free system (Fig. 4b, c). The
high reprogramming efﬁciency of this approach, in combination
Table 1 Generation of iPSCs from a variety of ﬁbroblast lines using the RNA-based approach
Fibroblast line Age (years old) Input cells per well TRA-1-60-positive colonies per well Efﬁciency (%)
FN1 Neonatal 500 3132 ± 240.04 626.4 ± 48.01
FN2 Neonatal 500 3896 ± 131.14 779.2 ± 26.23
FN5 Neonatal 500 2161.7 ± 258.8 432.3 ± 51.76
F40 40 2000 1453.3 ± 93.33 72.67 ± 4.67
F62 62 3000 1828 ± 201.5 60.93 ± 6.72
F50 50 5000 1821.7 ± 90.5 36.43 ± 1.81
F50S 50 (senescent) 100,000 325 ± 88.66 0.33 ± 0.09
FD54 Neonatal 3000 129.3 ± 52.62 4.31 ± 1.76
FEH1 7 1000 405.7 ± 14.57 40.57 ± 1.46
FEB1 23 3000 363.7 ± 44.5 12.1 ± 1.5
FRD1 21 3000 125.7 ± 33.13 4.2 ± 1.1
Primary neonatal ﬁbroblast lines: FN1, FN2, and FN5
Healthy primary adult ﬁbroblast lines: F40, F62, and F50
A senescent ﬁbroblast line derived from F50: F50S
Disease-associated ﬁbroblast lines: Down syndrome (FD54), epidermolytic ichthyosis (FEH1), epidermolysis bullosa simplex (FEB1), and recessive dystrophic epidermolysis bullosa (FRD1)
Values are reported as mean ± s.d. (n= 3)
iPSC Induced pluripotent stem cell
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Fig. 2 Deﬁning the minimal and the optimal number of RNA transfections for the RNA-based reprogramming approach. Summary plots and representative
TRA-1-60-stained reprogramming wells show the yield of TRA-1-60-positive colonies at day 18 of reprogramming initiated at a plating density of 500 cells
per well of a 6-well format dish with two independent human primary neonatal ﬁbroblast lines, FN1 (top) and FN2 (bottom). The reprogramming was
accomplished using the indicated numbers of mod-mRNA and m-miRNA transfections performed at either 48 or 72 h intervals using Opti-MEM-8.2 as the
transfection buffer. The amount of m-miRNA used per transfection is 20 pmol, and the amount of mod-mRNAs is indicated. Error bars, mean ± s.d. (n= 3).
No statistical difference in the reprogramming efﬁciencies was observed between 6 and 7 transfections (NS, P > 0.05). P values were calculated using the
unpaired two-tailed Student’s t test. Scale bars, 10mm
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with the small number of input cells, may especially beneﬁt the
clinical application of iPSCs as it potentially reduces the accu-
mulation of mutations that arise in iPSCs due to extensive cul-
turing of patient’s cells or selective reprogramming of mutated
founder cells. Our results also suggest that the reprogramming
efﬁciency for other cell types may be greatly improved by opti-
mizing protocols in a cell-type-speciﬁc manner.
The high reprogramming efﬁciency observed in our optimized
protocol may seem at odds with previous reports that show only a
modest improvement in reprogramming efﬁciency following the
combined treatment with mod-mRNAs and pluripotency-
inducing miRNAs6,7. Here, we enhanced the efﬁciency of a
combinatorial mod-mRNA/miRNA-based reprogramming strat-
egy by optimizing the transfection efﬁciency of reprogramming
factors, carefully titrating the amount of mod-mRNAs, and
identifying the optimal cell culture conditions that would allow
for the maximum proliferation of ﬁbroblasts (see the model in
Fig. 8).
First, we were able to initiate reprogramming at a low density
under feeder-free conditions, addressing a known limitation of
mod-mRNA-based reprogramming that requires a substantial
number of input cells for successful iPSC generation6,15. The
initial low seeding density encouraged input cells to go through
more cell cycles during reprogramming, potentially allowing for
more efﬁcient chromatin remodeling and improved reprogram-
ming efﬁciency (Fig. 7b and Supplementary Fig. 16b). In agree-
ment with this assumption, the expression of ASF1A, a histone-
remodeling protein important for cellular reprogramming,
remained high throughout our protocol and correlated with the
cell expansion rate (Fig. 7c and Supplementary Fig. 16c).
Second, we reduced the cytotoxic and immunogenic effect of
repetitive mod-mRNA transfections by ﬁne-tuning the
transfection regimen and by supplementing the reprogramming
process with miRNA-367/302s as mature miRNA mimics. The
addition of m-miRNAs appears to be critical for the reduction of
exogenous mod-mRNA levels to the optimum capable of indu-
cing efﬁcient reprogramming. The exclusion of m-miRNAs from
the protocol reduced the efﬁciency of reprogramming and
affected the stability of the resulting iPSCs. Our approach requires
less mod-mRNAs per transfection and performs more con-
sistently with every other day transfections. As a result, the
regimen prevents the induction of a robust innate immunity
response as shown by the low activation of innate immunity
genes (Fig. 7a and Supplementary Figs. 15a, 16a, and 17a).
Nevertheless, the commonly used inhibitor of interferon response
B18R was still used in our optimized protocol (see Methods
section). While the current trend in the ﬁeld is to increase the
delivery or expression levels of reprogramming factors to improve
the efﬁciency of iPSC generation, we have shown that efﬁcient
reprogramming can be achieved by balancing rather than simply
enhancing the expression level of factors. An example of balan-
cing the efﬁciency of transfection with the amount of mod-
mRNAs is shown in the experiment where we used PBS (pH 7.9)
as the transfection buffer. In this experiment, the reprogramming
efﬁciency was improved by either reducing the amount of 5fM3O
mod-mRNAs used per transfection from 600 to 200 ng or by
decreasing the pH of PBS to 7.3 (Fig. 1c, e and Supplementary
Fig. 3b, d), which consequently decreased the transfection efﬁ-
ciency of mod-mRNAs (Fig. 1a and Supplementary Fig. 3a).
The combination of a reprogramming mod-mRNA cocktail
with m-miRNAs not only prevented the robust activation of an
innate immunity response, but also appeared to have a synergistic
effect on reprogramming. Although the synergism between
reprogramming mod-mRNAs and m-miRNAs has been pre-
viously suggested6,7, it has never been shown at such a dramatic
level as reported here. This synergistic effect can be especially
appreciated in our single-cell reprogramming experiments, where
the exclusion of m-miRNAs from the reprogramming cocktail
drastically diminished the ability of individually plated cells to
undergo reprogramming (Fig. 4b). This synergism is most likely
mediated by the ability of reprogramming m-miRNAs to increase
cell cycling and to target multiple pluripotency-associated and
differentiation-associated pathways that overlap with the action
of reprogramming transcription factors. As an example, we
showed that the chromatin modiﬁer TET1 and the strong inducer
of pluripotency SALL4 were both robustly activated in response
to the delivery of m-miRNAs alone. These genes exhibited even
faster kinetics of activation in our optimized protocol (Fig. 7c and
Supplementary Fig. 16c). SALL4 has previously been shown to
promote an ordered activation of ESC-speciﬁc miRNAs, which is
associated with a higher reprogramming efﬁciency23. Therefore,
our ﬁndings suggest a role for SALL4 in mediating the synergism
between mod-mRNAs and m-miRNAs during reprogramming.
Our optimized regimen reprograms up to 90.7% of individually
plated human primary neonatal ﬁbroblasts (Fig. 4b) and gen-
erates iPSCs from primary neonatal and adult human ﬁbroblasts
with a 100% success rate, albeit with variable efﬁciencies
(Table 1). Despite these results, the reprogramming process is not
completely penetrant. Many non-reprogrammed TRA-1-60-
negative cells remain at the end of our protocol despite the
high number of iPSC colonies generated. Since rapid cell division
may cause continuous dilution of exogenous reprogramming
factors and prevent the maintenance of reprogramming factor
expression at levels sufﬁcient to achieve simultaneous repro-
gramming in all founder cells, deterministic reprogramming may
be difﬁcult to achieve with an RNA-based approach. Interestingly,
while our method reprogramed patient’s ﬁbroblasts with a high
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Fig. 3 The efﬁciency of the RNA-based reprogramming approach using
different m-miRNA concentrations. Summary table and representative
TRA-1-60-stained reprogramming wells show the yield of TRA-1-60-
positive colonies at day 18 of the optimized RNA-based reprogramming
regimen (Fig. 1b) performed with differing amounts of m-miRNAs as
indicated. The protocol was initiated with two independent human primary
neonatal ﬁbroblast lines (FN1 and FN2) plated at a density of 500 cells per
well of a 6-well format dish. The reprogramming efﬁciency was calculated
by dividing the number of resulting TRA-1-60-positive colonies by the
number of input cells and multiplying by 100%. Mean ± s.d. (n= 3). Scale
bar, 10mm
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reprogramming the established BJ ﬁbroblast line. This suggests
that established, long-lived ﬁbroblast lines, which are commonly
used as reference lines for reprogramming protocols, may not be
an ideal representative of human primary ﬁbroblasts’ behavior
during reprogramming.
In conclusion, the ultra-high reprogramming efﬁciency of our
integration-free approach addresses the current limitations of
reprogramming techniques for potential clinical applications and
for studying the mechanisms of human somatic cell reprogram-
ming. Our results also emphasize the importance of ﬁnding the
optimal cell-type-speciﬁc conditions to reveal the full synergistic
potential of exogenous mod-mRNAs and miRNAs in repro-
gramming somatic cells.
Methods
Generation of IVT templates. Production of in vitro transcription (IVT) tem-
plates for mod-mRNA generation was adapted from Warren et al14. Brieﬂy,
plasmids used as template for PCR for IVT template preparation were obtained
from Addgene: pcDNA3.3_KLF4 (catalog # 26815); pcDNA3.3_OCT4 (catalog #
26816); pcDNA3.3_SOX2 (catalog # 26817); pcDNA3.3_c-MYC (catalog # 26818);
pcDNA3.3_LIN28A (catalog # 26819); pcDNA3.3_d2eGFP (catalog # 26821).
Additional plasmids with inserts encoding mWasabi, human NANOG, and M3O






100,000 0.33 ± 0.58 0.0003 ± 0.0006
50,000 4.7 ± 6.43 0.0093 ± 0.0129
10,000 663.7 ± 302.74 6.64 ± 1.64
5000 1113.7 ± 151.28 22.27 ± 3.03
1000 3408.7 ± 163.9 340.87 ± 16.39
500 3896 ± 131.14 779.2 ± 26.23
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Fig. 4 Low initial cell plating densities improve the efﬁciency of the RNA-based reprogramming approach. a Summary table and representative TRA-1-60-
stained reprogramming wells showing the yield of TRA-1-60-positive colonies at day 18 of the optimized RNA-based reprogramming regimen (see Fig. 1b)
initiated with human primary neonatal ﬁbroblasts (FN2) at the indicated cell plating numbers per well of a 6-well format dish. The efﬁciency was calculated
by dividing the number of resulting TRA-1-60-positive colonies by the number of input cells and multiplying by 100%. Mean ± s.d. (n= 3). Scale bar, 10
mm. Similar results were obtained using an independent primary neonatal ﬁbroblast line, FN1 (Supplementary Fig. 5). b Summary table showing the
reprogramming of individually plated single cells with the 5fM3O mod-mRNA reprogramming cocktail delivered alone or in combination with m-miRNAs
every 48 h using Opti-MEM adjusted to a pH of 8.2 as the transfection buffer (see Fig. 1b). The number of individually plated single cells from three
independent primary neonatal ﬁbroblast lines (FN1, FN2, and FN5), the survival of these cells throughout reprogramming, and the resulting number of wells
with at least one TRA-1-60-positive colony at day 18 of reprogramming are shown. The efﬁciency was calculated by dividing the number of wells with TRA-
1-60-positive colonies by the number of wells with surviving input cells and multiplying by 100%. Representative TRA-1-60-stained reprogramming wells
(48-well dish format) correspond to conditions from the summary table. Note the formation of multiple sister TRA-1-60-positive colonies when both mod-
mRNA and m-miRNA transfections were employed. Scale bar, 3 mm. c Representative day-by-day images of single-cell reprogramming (FN2) performed
with the optimized RNA-based reprogramming approach. Staining for TRA-1-60 performed on day 18 of reprogramming is also shown. Scale bar, 100 µm
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template preparation were cloned using the following Addgene plasmids: pTEC15
(mWasabi, catalog # 30174); pGEM-NANOG (catalog # 16351); pMXs-hM3O-IP
(catalog # 46645). IVT templates were PCR generated using listed plasmids as
templates. Forward primer is 5′-TTGGACCCTCGTACAGAAGCTAATACG-3′




were synthesized by Integrated DNA Technologies. Reverse primer was synthesized
as Ultramer oligos at a 4 nmol scale.
Preparation of mod-mRNAs and m-miRNAs. Mod-mRNA was synthesized as
described with slight modiﬁcations14. Speciﬁcally, 1.6 µg of template PCR product
was provided for each 40 µl reaction of MEGAscript T7 Kit (Life Technologies). A
2.5× custom ribonuleoside mix including 15 mM 3′-0-Me-m7G(5′)ppp(5′)G
ARCA cap analog (New England Biolabs), 3.75 mM guanosine triphosphate and
18.75 mM adenosine triphosphate (both were used from MEGAscript T7 Kit), and
18.75 mM 5-methylcytidine triphosphate and 18.75 mM pseudouridine tripho-
sphate (TriLink Biotechnologies) was prepared. RNA synthesis reactions were
incubated at 37 °C for 6 h and then treated with DNase for 15 min at 37 °C as
directed by the manufacturer. RNA was puriﬁed with RNeasy Mini Kit columns
(Qiagen) and then treated with Antarctic Phosphatase (New England Biolabs) for
30 min at 37 °C. After re-puriﬁcation, RNA was eluted with nuclease-free dH2O
supplemented with 1 U/µl of RIBOGUARDTM RNase Inhibitor (Epicentre Bio-
technologies). RNA was then quantitated by Nanodrop (Thermo Scientiﬁc) and
stored at −80 °C until further use.
Unless otherwise noted, the mod-mRNA mix used for reprogramming
(“reprogramming cocktail”) contained 6 human reprogramming factors, M3O
(MyoD-Oct4)19, SOX2, KLF4, cMYC, NANOG, and LIN28A (abbreviated as
“5fM3O mod-mRNAs”), at a molar stoichiometry of M3O to the other 5 factors as
3:1:1:1:1:1 and included 10% mWasabi mod-mRNA to control for transfection
efﬁciency. A similar ratio of mod-mRNAs was maintained when OCT4 was used
instead of M3O in the 6-factor reprogramming cocktail (abbreviated as “5fOCT4
mod-mRNAs”). As a negative control for reprogramming (d2eGFP), the 6-factor
reprogramming cocktail was substituted with the mod-mRNA mix containing 90%
destabilized eGFP (d2eGFP) mod-mRNA and 10% mWasabi mod-mRNA. For
reprogramming and transfection experiments, the mod-mRNA mix or mWasabi
mod-mRNA alone were prepared at 100 ng/µl in nuclease-free water.
miRNA-367/302s as miScript miRNA mimics (Syn-has-miR-367-3p, Syn-has-
miR-302a-3p, Syn-has-miR-302b-3p, Syn-has-miR-302c-3p, and Syn-has-miR-
302d-3p) or miRNA negative controls (AllStars Negative Control siRNA and
ﬂuorescently labeled AllStars Negative siRNA AF 488) were purchased from
Qiagen. Lyophilized products were dissolved at a 5 µM ﬁnal concentration in
nuclease-free water. Individual m-miRNA-367/302s stocks were mixed in 1:1:1:1:1
ratio to prepare a 5 µM combined m-miRNA reprogramming cocktail.
Cells. Three independent human primary neonatal ﬁbroblasts lines (FN1, FN2,
and FN5), two healthy adult primary ﬁbroblasts lines (F50 and F40), and a neonatal
ﬁbroblast line from an individual with Down syndrome (FD54) were obtained
from ATCC. The primary ﬁbroblast cell line from a 62-year-old patient (F62) was
obtained from Lonza. Fibroblasts from patients with inherited skin blistering dis-
eases: epidermolytic ichthyosis with a heterozygous dominant p.[Asn188Ser]
mutation in the KRT1 gene (FEH1), severe generalized epidermolysis bullosa
simplex with a heterozygous dominant p.[Arg125Cys] mutation in the KRT14 gene
(FEB1), and severe generalized recessive dystrophic epidermolysis bullosa (EB24)
with a homozygous c.[6508C>T];[6508C>T], p.[Gln2170*];[p.Gln2170*] mutation
in the COL7A1 gene (FRD1)24 were isolated from skin biopsies obtained with
informed consent and with an approval from the local institutional review board
committees (COMIRB and Medisch Ethische Commissie UMCG). H1 (WA01)
and H9 (WA09) hESC lines were obtained from WiCell. A senescent ﬁbroblast line
(F50S) was obtained by serial passaging of F50 ﬁbroblasts in ﬁbroblast medium
containing minimum essential medium (MEM) supplemented with 10% heat-
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Fig. 5 Successful reprogramming of senescent human ﬁbroblasts. a Adult human primary ﬁbroblasts from a 50-year-old patient (F50) were passaged until
they reached 46 population doublings (PDs), at which point the cells stopped dividing, and started exhibiting a senescent phenotype with an enlarged
cellular morphology and 91% positivity for senescence-associated β-galactosidase (F50S). Scale bar, 200 µm. b Elongation of telomeres in iPSCs generated
from F50 and F50S. The length of telomeres in the indicated cell lines was measured by qPCR analysis. Error bars, mean ± s.d. (n= 3). Prolonged ﬁbroblast
passaging of F50 resulted in a signiﬁcant shortening of telomeres in F50S (***P < 0.001). P values were calculated using the unpaired two-tailed Student’s t
test. c Immunoﬂuorescent analysis showing expression of a panel of pluripotency markers in iPSC lines derived from F50S (I50S-1 and I50S-2). See Fig. 6b
and Supplementary Figs. 11 and 12 for controls and iPSC lines derived from F50. Scale bar, 250 µm. d Immunostaining showing expression of the neuronal
marker βIII-Tubulin (TUJ1) (ectoderm), and the endoderm-speciﬁc cytokeratin Endo-A in iPSCs derived from F50S subjected to directed differentiation. See
Fig. 6d for directed differentiation of iPSC lines derived from F50. Scale bar, 250 µm. e Hematoxylin and eosin staining and immunoﬂuorescent analysis of
consecutive sections of teratomas derived from I50S-1 and I50S-2 showing histology and marker expression speciﬁc to ectoderm (βIII-Tubulin (TUJ1),
neural tissues), mesoderm (vimentin, connective tissues), and endoderm (Endo-A, endothelium). See Fig. 6e for iPSC lines derived from F50.
Scale bar, 250 µm
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inactivated fetal bovine serum (HI-FBS), 1× MEM non-essential amino acids
solution, 55 µM of 2-mercaptoethanol (β-ME), 1× GlutaMAXTM supplement, plus
antibiotics (all from Thermo Fisher Scientiﬁc), until the cells reached 46 population
doublings (PDs). Senescence was conﬁrmed by β-galactosidase activity using a
Senescence β-Galactosidase Staining Kit (Cell Signaling Technology) according to
the manufacturer’s instruction.
Pluripotent stem cells were cultured in a 5% O2/5% CO2 tissue culture
incubator and maintained either in N2B27 medium comprising a mixture of
Dulbecco's modiﬁed Eagle's medium/F12 (DMEM/F12) and Neurobasal medium
(Thermo Fisher Scientiﬁc) at a 1:1 ratio, 1× MEM non-essential amino acids
solution, 1× GlutaMAXTM supplement, 55 µM β-ME, 1× N2 supplement (Thermo
Fisher Scientiﬁc), 1× B27 supplement (Thermo Fisher Scientiﬁc), 50 µg/ml L-
ascorbic acid (Sigma-Aldrich), 0.05% bovine serum albumin (BSA), 50 U/ml
penicillin–streptomycin, and 100 ng/ml basic FGF (bFGF) (Thermo Fisher
Scientiﬁc) on mitomycin C-inactivated human primary neonatal ﬁbroblasts as a










































































































Fig. 6 Characterization of the pluripotency of selected iPSC lines. a Principal component analysis of the RNA-Seq gene expression data performed on
selected iPSC lines (orange circles) and their corresponding parental ﬁbroblasts (blue squares), as well as on two human ESC lines (H1 and H9, black
triangles), documenting the close clustering of iPSCs with H1 and H9. All IN2 iPSC lines were derived from FN2, I50 from F50, and I50S from F50S (see
also Supplementary Table 1). b Immunoﬂuorescent analysis showing expression of selected pluripotency markers in the indicated iPSC lines. H9 human
ESCs and FN2 ﬁbroblasts are included as positive and negative controls, respectively. See Fig. 5c and Supplementary Figs. 11 and 12 for the analysis of
additional iPSC lines. c Bisulﬁte sequencing of the OCT4 promoter region in a selected iPSC line and its parental ﬁbroblast line. H9 human ESCs are included
as a control. The closed circles indicate methylated sites of the analyzed region. d Immunostaining showing expression of the neuronal marker βIII-Tubulin
(TUJ1) (ectoderm), and the endoderm-speciﬁc cytokeratin Endo-A in the indicated iPSC lines subjected to directed differentiation. e Hematoxylin and eosin
staining and immunoﬂuorescent analysis of consecutive sections of teratomas derived from indicated iPSC lines showing histology and marker expression
speciﬁc to ectoderm (βIII-Tubulin (TUJ1), neural tissues), mesoderm (vimentin, connective tissues), and endoderm (Endo-A, endothelium). See Fig. 5e and
Supplementary Fig. 13 for teratoma analysis of additional iPSC lines. All scale bars, 250 µm
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with Geltrex® Matrix (Thermo Fisher Scientiﬁc) at 100× dilution according to the
manufacturer’s instruction. Y-27632 (Sigma-Aldrich) was used with each passaging
at a ﬁnal concentration of 10 μM to improve the survival of pluripotent stem cells.
The medium was replaced daily. Y-27632 was removed the next day after each new
passage, and iPSCs were cultured without Y-27632 until the next passage. All cell
lines used in the study were tested negative for mycoplasma using Universal
Mycoplasma Detection Kit (ATCC).
The cumulative PD level in Fig. 7b and Supplementary Fig. 16b was calculated
by using the formula: PD= log(nf/ni)/log 2, where ni is the initial number of cells
and nf is the ﬁnal number of cells at each time point described in Supplementary
Fig. 14.
RNA transfection. Transfections with mod-mRNAs (encoding mWasabi, d2eGFP,
and reprogramming factors), m-miRNAs, and control siRNAs were performed
using Lipofectamin® RNAiMAXTM (RNAiMAX) (Thermo Fisher Scientiﬁc). RNA
and RNAiMAX were ﬁrst diluted in either pH-adjusted Opti-MEM® I Reduced
Serum Medium (Opti-MEM) (Thermo Fisher Scientiﬁc) or 1× pH-adjusted PBS as
indicated in the corresponding ﬁgures. pH-adjusted Opti-MEM or pH-adjusted
PBS were used as transfection buffers for complex formation between RNAiMAX
and RNA. Given that the pH of transfection buffers may affect the resulting
transfection efﬁciency, a range of pH values was tested. The pH of Opti-MEM and
1× PBS (Ambion) was adjusted to indicated values with 1M NaOH and 1M HCl at
room temperature (RT). For mod-mRNA transfections, 100 ng/µl RNA was diluted
5×, and 5 µl of RNAiMAX per microgram of mod-mRNAs was diluted 10× using
either pH-adjusted Opti-MEM or pH-adjusted PBS. After dilution, these compo-
nents were combined together and incubated for 15 min at RT. For the m-miRNA
transfections, a 5 µM (5 pmol/µl) m-miRNA mix was diluted to 0.6 pmol/µl, and 1
µl of RNAiMAX per 6 pmol of m-miRNAs was diluted 10× using either pH-
adjusted Opti-MEM or pH-adjusted PBS as indicated in the corresponding ﬁgures.
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15 min at RT. After incubation at RT, transfection mixtures of mod-RNA mix and/
or m-miRNA mix and RNAiMAX were applied to the cell cultures.
Transfection experiments. Human primary neonatal ﬁbroblasts were cultured at
low conﬂuency in ﬁbroblast medium until transfection. One day before transfec-
tion, tissue culture 6-well format dishes (Corning) were coated with Geltrex®
Matrix at 100× dilution in plain DMEM/F12 (Thermo Fisher Scientiﬁc). Primary
patient neonatal and adult ﬁbroblasts were plated onto the Geltrex-coated dishes at
50,000 cells per well of a 6-well format dish. The plating medium was comprised
KOSR medium (DMEM/F12 with L-glutamine and no HEPES (catalog # 11320),
20% KOSR, 0.5× MEM non-essential amino acid solution, 0.5× GlutaMAX™
Supplement, 55 µM β-ME, 1× antibiotic–antimycotic solution (all from Thermo
Fisher Scientiﬁc), and 50 µg/ml L-ascorbic acid) supplemented with 100 ng/ml
bFGF, 200 ng/ml B18R (eBioscience), and 5% HI-FBS (Thermo Fisher Scientiﬁc).
The plated cells were incubated overnight in a low O2 (5%)/5% CO2 tissue culture
incubator. The following day, the medium was changed to KOSR medium equi-
librated overnight at 5% O2/5% CO2 supplemented with fresh 100 ng/ml bFGF and
200 ng/ml B18R. The volume used per well of a 6-well format dish was 1 ml. RNA
transfections were performed as described above. The transfection efﬁciency of
mWasabi mod-mRNA or Alexa Fluor 488-conjugated AllStars Negative siRNA
achieved with different transfection buffers was determined by ﬂuorescence-
activated cell sorting (FACS) using an LSR II ﬂow cytometer (BD Instruments) and
analyzed using FlowJo software (Tree Star).
Control mRNA reprogramming. Control feeder-free mRNA reprogramming
(Supplementary Fig. 1) was performed as previously described15. Speciﬁcally,
primary neonatal ﬁbroblasts were plated onto dishes coated with CELLstartTM
(Thermo Fisher Scientiﬁc) in accordance with the manufacturer’s instructions at
densities ranging from 10,000 to 100,000 cells per well of a 6-well format dish in
PluritonTM medium (Stemgent) supplemented with 200 ng/ml B18R (eBioscience).
Media were replaced daily before and after mod-mRNA transfections. B18R sup-
plementation was discontinued the day after the ﬁnal transfection. Eleven daily 24-
h-long transfections of 5fM3O mod-mRNAs were performed as described above
using RNAiMAX and unadjusted Opti-MEM at its original pH of 7.2–7.3 as the
transfection buffer. A mRNA dose of 800 ng per well was delivered with each
transfection. The amount of mRNA was reduced to 200, 400, and 600 ng on the
ﬁrst three transfections. Adjusting the pH of Opti-MEM in the control mRNA
reprogramming, as well as the co-transfection with 20 pmol of m-miRNAs every
48 h, resulting in substantial cytotoxicity and complete cell death by day 4 of
reprogramming.
Optimization of RNA-based reprogramming. Except for KOSR medium, other
media such as E8, N2B27, PluritonTM, and mTeSRTM1 (STEMCELL Technologies)
failed to support the growth of low-density ﬁbroblast cultures during co-
transfections with 5fM3O mod-mRNAs and m-miRNAs in our initial prescreening
experiments. For optimizations and iPSC generation, primary patient’s neonatal
and adult ﬁbroblasts (except for FD54 and F62) were plated onto Geltrex-coated
dishes at densities ranging from 200 to 100,000 cells per well of a 6-well format dish
in KOSR medium supplemented with 5% HI-FBS, 100 ng/ml bFGF, and 200 ng/ml
B18R. Down syndrome patient’s ﬁbroblasts and F62 were reprogrammed using the
deﬁned, human recombinant Laminin-521 matrix (Thermo Fisher Scientiﬁc),
applied according to the manufacturer’s instruction. Laminin-521 appeared to be
more consistent for reprogramming of ﬁbroblasts than Geltrex. Laminin-521 is also
more appropriate for clinical and research applications due to its low batch-to-
batch variability. We also tested another deﬁned matrix, CELLstart, and found it to
be compatible with the protocol. The plated cells were incubated overnight in a low
O2 (5%)/5% CO2 tissue culture incubator. The following day the medium was
changed to KOSR medium equilibrated overnight at 5% O2/5% CO2 supplemented
with fresh 100 ng/ml bFGF and 200 ng/ml B18R. The ﬁrst transfection was per-
formed 1 h after changing the medium. RNA transfections were performed as
described above using pH-adjusted Opti-MEM or pH-adjusted PBS as indicated in
corresponding ﬁgures. Differing amounts of mod-mRNAs and m-miRNA were
used as described below (for the optimized regimen and single-cell reprogram-
ming) and in corresponding ﬁgures. For reprogramming into iPSCs, the mod-
mRNA transfection mix was applied ﬁrst separately followed by the m-miRNA
mix. Note that under every transfection condition, the cell growth medium was
KOSR medium, whereas complex formation between Lipofectamine and mod-
mRNAs or m-miRNAs was performed in either Opti-MEM or PBS at the indicated
pH. Three to seven transfections were performed every 48 h, as shown in Figs. 1b
and 2. Regimens with transfections performed every 24, 48, or 72 h were also
tested. In the 24 h regimen, 11 consecutive transfections were performed. In the 48
h regimen, up to seven transfections were performed. In the 72 h regimen, a
maximum of ﬁve transfections were performed. KOSR medium was changed
within 20–24 h after each transfection. KOSR medium was equilibrated overnight
at 5% O2/5% CO2 before each medium change and supplemented with fresh 100
ng/ml bFGF and 200 ng/ml B18R. The volume used per well of a 6-well format dish
was 1 ml. After completing the series of transfections, B18R supplementation was
discontinued and KOSR medium supplemented with 100 ng/ml bFGF was changed
every day. The cells were grown up to day 18 and then stained with anti-TRA-1-60
antibody (Stemgent, 09-0010) in combination with the horse radish peroxidase
(HRP)-conjugated anti-mouse secondary antibody (Thermo Fisher Scientiﬁc,
31432) using a standard immunocytochemistry technique. TRA-1-60-positive
colonies were visualized with NovaRED HRP substrate (Vector Laboratories). The
number of TRA-1-60-positive colonies was counted under Nikon Eclipse TE2000-S
inverted microscope with a 10× objective (Supplementary Fig. 18). The repro-
gramming efﬁciency was calculated by dividing the number of resulting TRA-1-60-
positive colonies by the number of input cells and multiplying by 100%. The
representative images of the plates were taken with Sony Alfa A77 Camera
equipped with the 50 mm f/2.8 Macro A-Mount Lens. The contrast and brightness
of the images were adjusted with Adobe Photoshop. For the optimized RNA-based
reprogramming approach (Fig. 1b) performed in a 6-well format dish, the amount
of the reprogramming mod-mRNA mix per well per transfection was 600 ng for
healthy neonatal ﬁbroblasts and 1,000 ng for adult and disease-associated ﬁbro-
blasts, and the amount of m-miRNAs per well per transfection was 20 pmol with
seven RNA transfections being performed every 48 h using RNAiMAX and Opti-
MEM adjusted to pH 8.2 as the transfection buffer. The higher amount of mod-
mRNAs (1,000 ng per transfection) appeared to be more consistent for adult and
disease-associated ﬁbroblasts. This amount can also be used for neonatal ﬁbroblasts
without losing reprogramming efﬁciency (Fig. 1c, d and Supplementary Fig. 3b, c).
The iPSC colonies designated for the maintenance and characterization were
manually picked on days 15–18 and plated either on Geltrex-coated tissue culture
dishes in E8 medium supplemented with 10 µM Y-27632 or onto a mitomycin C-
inactivated human neonatal ﬁbroblast feeder layer in N2B27 medium supple-
mented with 100 ng/ml bFGF and 10 µM Y-27632. Y-27632 was removed the next
day, and the iPSC lines were passaged as described above.
In some experiments, negative siRNA as a control for m-miRNA transfections
was used in combination with the reprogramming mod-mRNA mix. Negative
siRNA was noted to be highly toxic for cells, reducing cell reprogramming
efﬁciency as compared to reprogramming with mod-mRNAs alone (Fig. 1 and
Supplementary Fig. 3).
Single-cell reprogramming. To overcome the cell stress caused by FACS, a lim-
iting dilution approach was employed. Human primary neonatal ﬁbroblasts were
plated at very low cell densities (<1 cell per well) onto Geltrex-coated 48-well plates
in KOSR medium supplemented with 5% HI-FBS, 100 ng/ml bFGF, and 200 ng/ml
Fig. 7 Reduced innate immunity response and increased cell expansion enhance RNA-based reprogramming. The time-course analysis of gene expression
was performed on human primary neonatal ﬁbroblasts (FN2) undergoing reprogramming under different regimens as described in Supplementary Fig. 14.
Fibroblasts were subjected to either a control mod-mRNA reprogramming regimen initiated at 50,000 cells per well of a 6-well format dish with mod-
mRNA delivered every 24 h as described in Supplementary Fig. 1 (control 5fM3O reprogramming, blue) or the optimized RNA-based reprogramming
protocol as described in Fig. 1b (5fM3O+m-miRNA), initiated at 500 cells per well (red), 10,000 cells per well (10k, green), or 50,000 cells per well (50k,
light brown) of a 6-well format dish with RNA transfections performed every 48 h. As controls, cultures seeded at the initial plating density of 500 cells per
well were transfected every 48 h with either reprogramming mod-mRNA alone (5fM3O, purple) or control d2eGFP mod-mRNA alone (d2eGFP, raspberry),
or in combination with reprogramming m-miRNAs (d2eGFP+m-miRNA, black). a Graphs showing normalized mRNA counts for exogenous mod-mRNAs
(Exo-mod-mRNAs) and innate immunity-related genes throughout the indicated reprogramming regimens as detected by the Nanostring nCounter Gene
Expression Assay. b Graphs summarizing population doubling (PD) and normalized mRNA counts for a set of cell cycle-associated genes throughout the
indicated reprogramming regimens as detected by the Nanostring nCounter Gene Expression Assay. c Graphs showing normalized mRNA counts for
selected pluripotency genes and chromatin modiﬁer genes throughout the indicated reprogramming regimens as detected by the Nanostring nCounter
Gene Expression Assay. The X-axis shows time points (days) at which the samples were collected for analysis during the reprogramming regimens. The Y-
axis indicates values of either normalized mRNA counts or PD as speciﬁed on the corresponding plots. The analysis of additional genes associated with
innate immunity, cell cycle, and pluripotency is shown in Supplementary Fig. 15. The results of the time-course analysis are reproducible using an
independent primary neonatal ﬁbroblast line, FN1 (Supplementary Figs. 16 and 17)
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B18R as described above. The following day, each well was screened under the
microscope to ensure that only 1 cell was seeded per well. The wells with no cells or
more than 1 cell were eliminated from the experiment. The amount of RNAs used
throughout the regimen was adjusted to the surface area based on 1,000 ng of the
reprogramming mod-mRNA mix and 20 pmol of m-miRNAs per transfection per
well of a 6-well format dish. For each well of a 48-well format dish, 150 µl of KOSR
medium supplemented with bFGF and B18R was used. For each transfection, 100
ng of 5fM3O mod-mRNAs and 2 pmol of m-miRNAs or no m-miRNA mix were
used per well of a 48-well format dish. Seven transfections were performed at 48 h
intervals as described in Fig. 1b using Opti-MEM adjusted to a pH of 8.2 as the
transfection buffer, and KOSR medium was changed within 20–24 h after each
transfection. At the end of the transfection series, the medium was changed every
day. Cells were grown up to day 18 and then stained with anti-TRA-1-60 antibody.
The wells with iPSC colonies were counted. Only wells with more than 10 cells
detected at day 18 of the regimen were included for the calculation of repro-
gramming efﬁciency. The reprogramming efﬁciency was calculated by dividing the
number of wells with TRA-1-60-positive colonies by the number of wells with
surviving input cells and multiplying by 100%. Representative images of the plates
were taken with a Sony Alfa A77 Camera equipped with a 50 mm f/2.8 Macro A-
Mount Lens. The experiment was performed with three independent human pri-
mary neonatal lines.
Statistical analysis. For statistical analyses, single pairwise comparisons were
calculated using the unpaired two-tailed Student’s t test with P < 0.05 (*), P < 0.01
(**), P < 0.001 (***), and P < 0.0001 (****) indicating signiﬁcance. The datasets used
for statistical comparison were also analyzed for normal distribution using the
Shapiro–Wilk test and for equal variance using the F test. Values are shown as
means with error bars depicting the standard deviation (s.d.).
Immunoﬂuorescence analysis and H&E staining. Cells were ﬁxed in 4% for-
maldehyde and permeabilized with 0.2% Triton X (Sigma) in 0.05% saponin
solution for 5 min. Cells were blocked with 10% BSA in PBS (Sigma) and 10%
donkey or goat normal serum (The Jackson Laboratory) in saponin solution for 1
h and then stained in blocking buffer at 4 °C overnight. Cells were washed with
saponin and stained with secondary antibodies for 2 h at RT. Tissues were ﬁxed
in 4% paraformaldehyde, embedded in parafﬁn, sectioned, and stained with
hematoxylin and eosin (H&E). For immunoﬂuorescence staining, slides were
deparafﬁnized by submerging in xylene, rehydrated through a gradient ethanol
bath, and the antigen was retrieved via boiling in 10 mM citrate buffer, pH 6.0
(Abcam). In the analysis of teratomas, the H&E staining and single-staining
immunoﬂuorescence analysis of expression of each germline-speciﬁc marker
(TUJ1, vimentin, and Endo-A) were performed on separate, consecutively cut
sections. Antibodies used were: Alexa Flour 488-conjugated anti-TRA-1-81
(Stemgent, 09-0069; 1:10); Alexa Fluor 555-conjugated anti-SSEA-4 (BD, 560218;
1:50); anti-OCT4 (Santa Cruz Biotechnology, sc-5279; 1:100), anti-NANOG
(R&D Systems, AF1997; 1:50); anti-SOX2 (Cell Signaling Technology, 3579S;
1:160); anti-LIN28A (Cell Signaling Technology, 8706S; 1:100); anti-Endo-A
(Developmental Studies Hybridoma Bank, TROMA-I; 1:100), anti-β-tubulin III
(TUJ1) (Covance, PRB435P; 1:5,000), anti-human vimentin (Abcam, 16700;
1:100). Secondary antibodies used were: Alexa Fluor 594 donkey anti-goat IgG
(H+ L) (A-11058) 1:250, Alexa Fluor 594 goat anti-mouse IgG (H+ L) (A-
11005) 1:250, Alexa Fluor 594 goat anti-rat IgG (H+ L) (A-11007), Alexa Fluor
594 goat anti-rabbit IgG (H+ L) (A-11037), and Alexa Fluor 488 goat anti-rabbit
IgG (H+ L) (A-11034), all from Thermo Fischer Scientiﬁc. After staining, slides
were mounted in mounting medium with DAPI (4',6-diamidino-2-phenylindole)
(Vector Laboratories). Images were acquired using a Nikon Eclipse 90i upright
microscope using a 10× objective. The contrast and brightness of the images were
adjusted with Adobe Photoshop.
Nanostring nCounter gene expression assay. Total RNA from the equivalent of
10,000 cells was used for the analysis with the nCounter system, according to the
manufacturer’s protocol (Nanostring Technologies). nCounter® Gene Expression
CodeSets for all experiments were custom-designed by Nanostring Technologies.
Supplementary Data 1 includes a CodeSet for the expression analysis of hTERT,
selected pluripotency-associated and ﬁbroblast-associated genes described in Sup-
plementary Fig. 10. Supplementary Data 2 includes a CodeSet for innate immunity,
cell cycle, and pluripotency genes analyzed in the reprogramming time-course
experiment described in Supplementary Fig. 14. The speciﬁc exogenous RNA (Exo-
mod-mRNA) probe was designed against the 3′-untranslated region (UTR) ele-
ment from the mouse α-globin gene. Probes for endogenous OCT4, NANOG,
SOX2, and LIN28A genes were designed to target speciﬁc UTR sequences to pre-
vent cross-reactivity with the reprogramming mod-mRNAs applied to ﬁbroblasts.
Digital RNA counting and data analyses were performed by Nanostring Tech-
nologies using nSolver® analysis software. Raw RNA counting data were normal-
ized to the mean of the positive control probes for each assay and to the geometric
mean of 5 housekeeping genes listed in Supplementary Datas 1 and 2. Probes for
housekeeping genes were chosen from the list provided by Nanostring
Technologies.
RNA-Seq analysis. Indexed samples were pooled, divided, and loaded onto eight
lanes of an Illumina HiSeq2000 ﬂow cell yielding 50-bp single-end reads. On
average 60 million reads were collected for each sample. The resulting sequences
were ﬁltered and trimmed to remove low-quality bases (Phred score < 15) from the
3′ ends of the reads using a custom Perl script. The remaining sequences were
mapped to the human genome (hg19) using GSNAP (version 2012-07-20)25. After
alignment, Cufﬂinks (version 2.2.1)26 was used to assemble transcripts and esti-
mate the gene expression values expressed as fragments per kilobase per million
(FPKM). In the programming language R, the FPKM values from all 14 samples
were used for the principal components analysis.
In vitro and in vivo differentiation analyses. The iPSCs were differentiated into
cells from a neuronal lineage using a protocol adapted from Hu et al.27 and
Chambers et al 28. Brieﬂy, iPSC cultures were disaggregated using collagenase type
I and feeder-depleted on gelatin for 30 min at 37 °C. The non-adherent cells were
collected and plated on a Geltrex-coated dish at a density of 25–30,000 cells/cm2 in
N2B27 medium supplemented with 100 ng/ml bFGF and 10 µM Y-27632. Y-27632
was removed the next day, and cells were allowed to expand until 80% conﬂuency.
Cells were then disaggregated following the procedure described above using col-
lagenase type I, and iPSC cell aggregates (embryoid bodies) were formed in sus-
pension culture on low-attachment tissue culture plates in N2B27 medium
supplemented with 250 ng/ml Noggin (R&D) and 10 µM SB431542 (Stemgent) for
the initial 4 days of differentiation. The formed aggregates were induced with
neural induction media containing Neurobasal medium supplemented with N2,
B27, and heparin for 14 days. The induction phase was followed by the differ-
entiation stage in Neurobasal medium supplemented with N2, B27, 1 µg/ml
laminin (Sigma), 100 nM cAMP (Sigma), 200 ng/ml ascorbic acid (Sigma), 10 ng/
ml brain-derived neurotrophic factor (Peprotech), 10 ng/ml glial cell-derived
neurotrophic factor (Peprotech), and 10 ng/ml IGF-I (Peprotech). At day 84 of
differentiation, cells were ﬁxed and processed for immunoﬂuorescence staining
with an antibody raised against neuron-speciﬁc βIII-Tubulin (TUJ1) as described
above.
The iPSCs were differentiated into cells from an endodermal lineage using a
previously published protocol29. Speciﬁcally, iPSCs were feeder-depleted and
seeded on a Geltrex-coated dish. These cells were then differentiated as a
monolayer at 70% conﬂuency. For the ﬁrst 4 days, RPMI medium (Gibco)
supplemented with 1× glutamine, 450 µM monothioglycerol (MTG) (Gibco), 2 µM
CHIR 99021 (Stemgent), 100 ng/ml Activin A (R&D), 50 µg/ml ascorbic acid, 25
ng/ml BMP4 (R&D), 5 ng/ml bFGF, and 10 ng/ml vascular endothelial growth
factor (VEGF) (R&D) was used. On day 5, cells were disaggregated with Accutase
and seeded at 250,000 cells per well on a Geltrex-coated dish. Cells were fed every
2 days until day 18 with media supplemented with cytokines provided above. At
day 18 of differentiation, cells were immunostained with an antibody against
endoderm-speciﬁc cytokeratin Endo-A using an immunostaining protocol as
described above.
The iPSCs were differentiated into cells of a cardiomyocyte lineage using a
previously published protocol with modiﬁcations30. Brieﬂy, cells were feeder-
depleted and seeded on a Geltrex-covered dish. These cells were then dissociated
using collagenase type I and placed in a suspension culture for embryoid body
formation in basic medium containing StemPro34 (Invitrogen), 2 mM glutamine,
150 µg/ml Transferrin (Roche), 400 µM MTG, 50 µg/ml ascorbic acid, and 10 ng/ml
BMP4. The following day, the cell aggregates were switched to induction medium
containing StemPro34 (Invitrogen), 2 mM glutamine, 150 µg/ml transferrin
(Roche), 400 µM MTG, and 50 µg/ml ascorbic acid, and supplemented with the
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Fig. 8 The mechanism underlying the enhanced reprogramming activity of
the optimized RNA-based approach. The schematic depicts the proposed
mechanism by which the optimized RNA-based reprogramming approach
improves the efﬁciency of cellular reprogramming. The reduced cytotoxicity
of the optimized mod-mRNA/miRNA-based reprogramming regimen in
combination with the low initial cell plating density, which allows for the
maximum proliferation of input cells, substantially enhances the efﬁciency
of iPSC generation
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and bFGF (2.5 ng/ml); days 3–5: VEGF (1.25 ng/ml) (R&D) and DKK1 (150 ng/ml)
(R&D); days 8–14: VEGF (1.25 ng/ml), DKK1 (150 ng/ml), and bFGF (2.5 ng/ml).
Beating cardiomyocytes were observed at day 14. The videos were taken using the
3i Marianas spinning disk confocal (3i-Intelligent Imaging Innovations Inc.,
Denver CO, USA) in a bright-ﬁeld mode via a transmitted light path. The software
used was Slidebook 5.5 (3i-Intelligent Imaging Innovations).
For teratoma analysis, iPSCs (1 × 106 cells) were injected subcutaneously into
the ﬂank of 6-week-old female SCID mice (The Jackson Laboratory). For each iPSC
line, two mice were injected. The animals were monitored for 2 months for the
formation of a tumor with terminal size limited to 2 cm. If both animals injected
with a single iPSC line developed tumors, only one randomly selected tumor was
analyzed. No other randomizations were performed. Investigators were not blinded
to the experimental groups. All experiments with mice were performed in
accordance with the regulations and approval of the University of Colorado Denver
Institutional Animal Care and Use Committee.
Karyotyping. The cytogenetic analysis was performed by the University of Col-
orado Cancer Center Molecular Pathology Shared Resource on ﬁxed cell pellets
using standard GTL banding (G-banding) of metaphase chromosomes. Metaphase
spreads were captured using a CCD camera and karyotyping was carried out using
BandView software (Applied Spectral Imaging Inc). Chromosome classiﬁcation
followed ISCN (2013) guidelines. From 13 to 15 chromosome spreads were ana-
lyzed from each cell line.
Cell line identity conﬁrmation. The identity of iPSC lines derived from FN2, F50,
and F50S was conﬁrmed by STR genotyping using the STR genotyping
AmpFLSTR® Identiﬁler® PCR Ampliﬁcation Kit (Thermo Fischer Scientiﬁc). The
STR genotypes of the generated iPSC lines matched those of primary ﬁbroblast
lines from which they had been derived. The identity of disease-associated iPSC
lines was conﬁrmed by the presence of either corresponding disease-causing
mutations or trisomy 21 (for Down syndrome lines).
Bisulﬁte sequencing. The promoter region of the human OCT4 gene was analyzed
as previously described with minor modiﬁcations21. Speciﬁcally, genomic DNA
from FN2 ﬁbroblasts, FN2-derived iPSCs (IN2–5) and hESCs (H9) was treated
with EpiTect Bisulﬁte Kit (Qiagen) according to the manufacture’s instruction. The
human OCT4 promoter sequence was ampliﬁed by PCR using primers: bi OCT4-S,
5′-TAGTTGGGATGTGTAGAGTTTGAGA-3′ and bi OCT4-AS, 5′-TAAAC-
CAAAACAATCCTTCTACTCC-3′. Generated PCR products were subcloned into
pGEM-T Easy vector system (Promega). Finally, ten random clones corresponding
to each original cell line were picked and sequenced.
Immunoblot analysis. Antibodies used for standard immunoblotting were: anti-
p21 (Santa Cruz Biotechnology, sc-469; 1:250), anti- β-actin (Santa Cruz Bio-
technology, sc-1616; 1:500), anti-rabbit IgG-HRP (Santa Cruz Biotechnology, sc-
2004; 1:5,000), anti-goat IgG-HRP (Santa Cruz Biotechnology, sc-2020; 1:5,000).
Signals were detected with “chemiluminescent” (Thermo Fisher Scientiﬁc). After
the detection of p21, the same blot was stripped and reprobed with the anti-β-actin
antibody as a loading control (see Supplementary Fig. 7b for uncropped scans of
the blot).
Telomere length analysis. The length of telomeres was measured using quanti-
tative PCR (qPCR)31. Speciﬁcally, DNA was isolated from low passage (F50) and
senescent (F50S) parental ﬁbroblasts, iPSC lines derived from F50 (I50-2 and I50-
3) and F50S (I50S-1 and I50S-2), and human ESCs (H1). qPCR analysis was
performed with telomere-speciﬁc and human single copy gene (SCG) control
primers, using LightCycle 480 (Roche). Telomere-speciﬁc primers are: teloF, 5′-
CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3′ and teloR, 5′-
GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3′. Human SCG
control primers are: 36B4F, 5′-CAGCAAGTGGGAAGGTGTAATCC-3′ and
36B4R, 5′-CCCATTCTATCATCAACGGGTACAA-3′.
Telomerase activity analysis. Telomerase activity was measured with the TRA-
PEZE Telomerase Detection Kit (Chemicon) according to the manufacturer’s
instructions. CHAPS (1×) lysis buffer was used to obtain extracts from parental
ﬁbroblasts (F50), iPSC lines derived from F50 (I50-2 and I50-3), and iPSC lines
derived from senescent F50S line (I50S-1 and I50S-2) and H1 ESC line. About
2,000 cells were assayed for each telomeric repeat ampliﬁcation protocol assay, and
800 cell equivalents were loaded into each well of a 15% non-denaturing TBE (Tris
borate, EDTA) polyacrylamide gel. Each sample was heat inactivated for 15 min at
85 °C to assess the background of the assay. Data were analyzed with Fluoro Chem
HD2 scanner.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles or
from corresponding author upon reasonable request. Nucleotide sequences for
RNA-Seq data have been deposited in the Gene Expression Omnibus database at
NCBI under accession code GSE97265.
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